Samsung, the South Korean conglomerate, plans to launch generic versions of biological medicines by 2015 at half the current western prices, as it gears up to challenge US and European pharmaceutical companies.
Tae-Han Kim, president of Samsung BioLogics, said his company aimed to complete a manufacturing plant outside Seoul by June, and win international regulatory approval for the factory by the end of this year.
Read the full article at Financial Times
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity